Bronchial Artery Embolization with Large Sized (700–900 µm) Tris-acryl Microspheres (Embosphere) for Massive Hemoptysis: Long-Term Results (Clinical Research)

2017 ◽  
Vol 41 (2) ◽  
pp. 225-230 ◽  
Author(s):  
Fahrettin Kucukay ◽  
Osman Melih Topcuoglu ◽  
Ayhan Alpar ◽  
Çetin Murat Altay ◽  
Murat Bulent Kucukay ◽  
...  
2000 ◽  
Vol 23 (5) ◽  
pp. 351-357 ◽  
Author(s):  
Akira Kato ◽  
Sho Kudo ◽  
Koichi Matsumoto ◽  
Tetsuhiro Fukahori ◽  
Toshihisa Shimizu ◽  
...  

2014 ◽  
Vol 23 (1) ◽  
pp. 55-60 ◽  
Author(s):  
Oren Fruchter ◽  
Sonia Schneer ◽  
Victoria Rusanov ◽  
Alexander Belenky ◽  
Mordechai R Kramer

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jung Han Hwang ◽  
Jeong Ho Kim ◽  
Suyoung Park ◽  
Ki Hyun Lee ◽  
So Hyun Park

Abstract Purpose To evaluate the safety, efficacy, and long-term outcome of bronchial artery embolization (BAE) in the treatment of non-massive hemoptysis and the prognostic factors associated with recurrent bleeding. Materials and methods From March 2005 to September 2014, BAE was performed in 233 patients with non-massive hemoptysis. All patients had a history of persistent or recurrent hemoptysis despite conservative medical treatment. We assessed the technical and clinical success, recurrence, prognostic factors related to recurrent bleeding, recurrence-free survival rate, additional treatment, and major complications in all the patients. Results Technical success was achieved in 224 patients (96.1%), and clinical success was obtained in 219 (94.0%) of the 233 patients. In addition, 64 patients (27.5%) presented hemoptysis recurrence with median time of 197 days after embolization. Tuberculosis sequelae and presence of aberrant bronchial artery or non-bronchial systemic collaterals were significantly related to recurrent bleeding (p < 0.05). The use of Histoacryl-based embolic materials significantly reduced the recurrent bleeding rate (p < 0.05). Patient who had a tuberculosis sequelae showed a significantly lower recurrence-free survival rate (p = 0.013). Presence of aberrant bronchial artery or non-bronchial systemic collaterals showed a statistically significant correlation with recurrence-free survival rate (p = 0.021). No patients had major complications during follow-up. Conclusions BAE is a safe and effective treatment to manage non-massive hemoptysis. The procedure may offer a better long-term control of recurrent hemoptysis and quality of life than conservative therapy alone.


1979 ◽  
Vol 95 (6) ◽  
pp. 959-963 ◽  
Author(s):  
Kenneth E. Fellows ◽  
Kon Taik Khaw ◽  
Samuel Schuster ◽  
Harry Shwachman

Radiology ◽  
1985 ◽  
Vol 157 (3) ◽  
pp. 637-644 ◽  
Author(s):  
R Uflacker ◽  
A Kaemmerer ◽  
P D Picon ◽  
C F Rizzon ◽  
C M Neves ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document